Terms: = Lung cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
29 results:
1. lung Fibroblasts Take up Breast cancer Cell-derived Extracellular Vesicles Partially Through mek2-dependent Macropinocytosis.
Wan Y; Zhao Y; Cao M; Wang J; Tran SV; Song Z; Hsueh BW; Wang SE
Cancer Res Commun; 2024 Jan; 4(1):170-181. PubMed ID: 38259097
[TBL] [Abstract] [Full Text] [Related]
2. Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells.
Ko JC; Chen JC; Hsieh JM; Tseng PY; Chiang CS; Liu LL; Chien CC; Huang IH; Chang QZ; Mu BC; Lin YW
Biochem Pharmacol; 2022 Oct; 204():115207. PubMed ID: 35961402
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacokinetic Interaction Between the MEK1/mek2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.
Arkenau HT; Taylor D; Xu X; Chitnis S; Llacer-Perez C; Moore K; Nidamarthy PK; Ilankumaran P; De Vos-Geelen J
Clin Pharmacol Drug Dev; 2022 May; 11(5):585-596. PubMed ID: 35157784
[TBL] [Abstract] [Full Text] [Related]
4. Connecting copper and cancer: from transition metal signalling to metalloplasia.
Ge EJ; Bush AI; Casini A; Cobine PA; Cross JR; DeNicola GM; Dou QP; Franz KJ; Gohil VM; Gupta S; Kaler SG; Lutsenko S; Mittal V; Petris MJ; Polishchuk R; Ralle M; Schilsky ML; Tonks NK; Vahdat LT; Van Aelst L; Xi D; Yuan P; Brady DC; Chang CJ
Nat Rev Cancer; 2022 Feb; 22(2):102-113. PubMed ID: 34764459
[TBL] [Abstract] [Full Text] [Related]
5. "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
Bade BC; Gan G; Li F; Lu L; Tanoue L; Silvestri GA; Irwin ML
BMC Cancer; 2021 Apr; 21(1):352. PubMed ID: 33794808
[TBL] [Abstract] [Full Text] [Related]
6. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract] [Full Text] [Related]
7. MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury.
Long ME; Gong KQ; Eddy WE; Volk JS; Morrell ED; Mikacenic C; West TE; Skerrett SJ; Charron J; Liles WC; Manicone AM
JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31801908
[TBL] [Abstract] [Full Text] [Related]
8. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH; Lopez Rodrigo E; Picarsic J; Abramson D; Rotemberg V; De Munck S; Pannecoucke E; Lu SX; Pastore A; Yoshimi A; Mandelker D; Ceyhan-Birsoy O; Ulaner GA; Walsh M; Yabe M; Petrova-Drus K; Arcila ME; Ladanyi M; Solit DB; Berger MF; Hyman DM; Lacouture ME; Erickson C; Saganty R; Ki M; Dunkel IJ; Santa-María López V; Mora J; Haroche J; Emile JF; Decaux O; Geissmann F; Savvides SN; Drilon A; Diamond EL; Abdel-Wahab O
Nat Med; 2019 Dec; 25(12):1839-1842. PubMed ID: 31768065
[TBL] [Abstract] [Full Text] [Related]
9. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract] [Full Text] [Related]
10. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell lung cancer After Platinum-Based Chemotherapy Treatment Failure.
Barbie DA; Spira A; Kelly K; Humeniuk R; Kawashima J; Kong S; Koczywas M
Clin Lung Cancer; 2018 Nov; 19(6):e853-e859. PubMed ID: 30087028
[TBL] [Abstract] [Full Text] [Related]
11. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.
Ozkaya N; Rosenblum MK; Durham BH; Pichardo JD; Abdel-Wahab O; Hameed MR; Busam KJ; Travis WD; Diamond EL; Dogan A
Mod Pathol; 2018 Apr; 31(4):581-597. PubMed ID: 29192649
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and Predictive Value in KRAS in Non-Small-Cell lung cancer: A Review.
Wood K; Hensing T; Malik R; Salgia R
JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
[TBL] [Abstract] [Full Text] [Related]
13. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
[TBL] [Abstract] [Full Text] [Related]
14. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
[TBL] [Abstract] [Full Text] [Related]
16. A randomized phase II study of the MEK1/mek2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
[TBL] [Abstract] [Full Text] [Related]
17. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
[TBL] [Abstract] [Full Text] [Related]
18. Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Chen JQ; Lee JH; Herrmann MA; Park KS; Heldman MR; Goldsmith PK; Wang Y; Giaccone G
Mol Cancer Ther; 2013 Nov; 12(11):2601-13. PubMed ID: 23979919
[TBL] [Abstract] [Full Text] [Related]
19. Trametinib: first global approval.
Wright CJ; McCormack PL
Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
[TBL] [Abstract] [Full Text] [Related]
20. MEK and the inhibitors: from bench to bedside.
Akinleye A; Furqan M; Mukhi N; Ravella P; Liu D
J Hematol Oncol; 2013 Apr; 6():27. PubMed ID: 23587417
[TBL] [Abstract] [Full Text] [Related]
[Next]
